A patient diagnosed with narcolepsy begins treatment with a standard psychomotor stimulant. After a month, they report that their excessive daytime sleepiness has only slightly improved, and they still experience frequent episodes of sudden muscle weakness triggered by laughter. Based on the typical challenges in treating this condition, what is the most appropriate next step for the healthcare provider to consider, and what is the underlying reason for this strategy?